Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026

Century Therapeutics reported data supporting scalable manufacturing, in vivo function and immune evasion for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diabetes. The company also provided an update indicating progress toward initiating clinical dosing, a positive development for the program's clinical advancement.